C1 inhibitor (Protein | Antibody | cDNA Clone | ELISA Kit)

All C1 inhibitor reagents are produced in house and quality controlled, including 5 C1 inhibitor Antibody, 2 C1 inhibitor ELISA, 52 C1 inhibitor Gene, 1 C1 inhibitor IP Kit, 2 C1 inhibitor Lysate, 2 C1 inhibitor Protein, 1 C1 inhibitor qPCR. All C1 inhibitor reagents are ready to use.

More Product Popular With Customers

C1 inhibitor Related Research Area

C1 inhibitor Background

Plasma protease C1 inhibitor, also known as C1-inhibiting factor, C1-INH, C1 esterase inhibitor, SERPING1 and C1IN, is a serine proteinase inhibitor (serpin) that regulates activation of both the complement and contact systems. By its C-terminal part (serpin domain), characterized by three beta-sheets and an exposed mobile reactive loop, C1-INH binds, and blocks the activity of its target proteases. The N-terminal end (nonserpin domain) confers to C1-INH the capacity to bind lipopolysaccharides and E-selectin. Owing to this moiety, C1-INH intervenes in regulation of the inflammatory reaction. The heterozygous deficiency of C1-INH results in hereditary angioedema (HAE). Owing to its ability to modulate the contact and complement systems and the convincing safety profile, plasma-derived C1 inhibitor is an attractive therapeutic protein to treat inflammatory diseases other than HAE. Deficiency of C1 inhibitor results in hereditary angioedema, which is characterized by recurrent episodes of localized angioedema of the skin, gastrointestinal mucosa or upper respiratory mucosa. C1 inhibitor may prove useful in a variety of other diseases including septic shock, reperfusion injury, hyperacute transplant rejection, traumatic and hemorrhagic shock, and the increased vascular permeability associated with thermal injury, interleukin-2 therapy and cardiopulmonary bypass.

C1 inhibitor References

  • Davis AE 3rd. et al. (2004) Biological effects of C1 inhibitor. Drug News Perspect. 17(7): 439-46.
  • Cicardi M, et al. (2005) C1 inhibitor: molecular and clinical aspects. Springer Semin Immunopathol. 27(3): 286-98.
  • Wouters D, et al. (2008) C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor. Expert Opin Biol Ther. 8(8): 1225-40.
  • Cugno M, et al. (2009) C1-inhibitor deficiency and angioedema: molecular mechanisms and clinical progress. Trends Mol Med. 15(2): 69-78.
彩票大奖得主捐赠 七乐彩9个中4多少钱 吉林11选5开奖时间 天天pk10免费计划软件安卓 云南十一选五下载 黑龙江快乐十分钟走势 江苏11选5胆拖中奖规则 阿里体育天天红包赛是平分吗 甘肃快三快三 安徽体彩十一选五一定牛 广西快3遗漏值统计快三